Qiming Corporate GP VI, Ltd. and affiliated Qiming entities filed a Form 4 with the SEC on November 3, 2026, disclosing sales of Alamar Biosciences, Inc. (NASDAQ:ALMR) common stock across multiple transactions on October 30, 2026 and November 2, 2026.

Key Highlights

  • Reporting person: Qiming Corporate GP VI, Ltd., identified as a 10% owner of Alamar Biosciences, Inc., filed jointly with six affiliated Qiming entities.
  • Transaction dates: Sales of common stock occurred on October 30, 2026 and November 2, 2026.
  • Price ranges: Shares were sold at weighted average prices of $29.93, $30.70, $31.96, and $33.31 on October 30, and at $29.84 and $30.63 on November 2, with individual transaction prices spanning from $29.50 to $33.59 across all sale events.
  • Post-transaction holdings via Qiming Venture Partners VI: Beneficial ownership in that entity fell to 6,008,639 shares following the October 30 sales and to 5,980,104 shares following the November 2 sales, according to the filing.
  • Post-transaction holdings via Qiming Managing Directors Fund VI: Ownership in that entity fell to 161,679 shares after October 30 sales and to 160,913 shares after November 2 sales.
  • All transactions coded "S": Every reported transaction carried transaction code S, indicating open-market sales, per the filing.
  • Beneficial ownership disclaimed: Each Qiming entity filing this report disclaims beneficial ownership of the shares it may be deemed to control, "except to the extent of its proportionate pecuniary interest therein," according to the filing's footnotes.

Qiming Entities Dispose of Alamar Biosciences Common Stock Across Two Trading Days

According to the Form 4 filed November 3, 2026, Qiming Corporate GP VI, Ltd. and six affiliated entities reported sales of Alamar Biosciences, Inc. common stock on October 30 and November 2, 2026. The shares were held indirectly through four distinct fund vehicles: Qiming Managing Directors Fund VI, L.P.; Qiming Venture Partners VI, L.P.; Qiming Venture Partners VIII Investments, LLC; and Qiming Venture Partners VIII-HC, L.P. Each entity had its own beneficial ownership count reported separately in Table I of the filing.

On October 30, 2026, the filing reports sales across four weighted average price points. For shares attributed to Qiming Venture Partners VI, the filing records sales of 48,659 shares at $29.93, 40,112 shares at $30.70, 3,400 shares at $31.96, and 1,169 shares at $33.31, leaving a post-transaction beneficial ownership of 6,008,639 shares in that vehicle. For shares attributed to Qiming Venture Partners VIII-HC, L.P., the filing records sales of 13,593, 11,205, 950, and 327 shares at the same respective price points, leaving 1,678,521 shares in that vehicle. The filing notes that all weighted average prices represent multiple transactions at prices within stated ranges, and the reporting person has undertaken to provide full per-price detail upon request.

On November 2, 2026, additional sales are reported at weighted average prices of $29.84 and $30.63. Across all four fund vehicles combined, the November 2 transactions reduced total reported beneficial ownership further. The filing identifies Qiming Corporate GP VI, Ltd. as the entity that, through direct and indirect general partner relationships, may be deemed to have voting and dispositive power over shares held in the respective funds, while disclaiming beneficial ownership beyond its proportionate pecuniary interest.

What Was Disclosed

The Form 4 discloses open-market sales of Alamar Biosciences common stock by Qiming Corporate GP VI, Ltd. and six affiliated entities on October 30 and November 2, 2026, across multiple price points ranging from $29.50 to $33.59, with updated beneficial ownership figures reported for each affiliated fund vehicle.